OBJECTIVE: The purpose of this study is to determine whether @entity1 with a discharge diagnosis of @entity162 were prescribed medications that are in accordance with evidence-based treatment guidelines and are FDA-approved for @entity162 . METHODS: A retrospective study was conducted to assess prescribing of evidence-based therapies for @entity1 discharged between November 2007 and August 2010 with a diagnosis code of BPD at the time of discharge. The primary objective of the study was to determine if evidence-based medications were prescribed at the time of discharge. Secondary objectives included analysis of other medications used, concomitant disease states and drug therapy, rate of readmission, and rate of therapeutic drug monitoring. RESULTS: Of 294 @entity1 , 170 (58%) were prescribed evidence-based medications upon discharge. The most commonly used medication was @entity1089 . The most commonly prescribed off-label medications were atypical antipsychotics. For patients on antipsychotics, rates of appropriate monitoring were variable. Seventy percent of @entity1 receiving @entity1091 had a therapeutic concentration prior to discharge. Differences in rates of readmission between groups were not significant. CONCLUSIONS: Rates of prescribing evidence-based medications at discharge for @entity1 with BPD were low. Additionally, evidence-based monitoring for specific medications was variable. Future studies reviewing treatment course and illness severity may provide more information about appropriate medication use in @entity1 with BPD.

Adherence to evidence-based treatment guidelines for XXXX in an inpatient setting.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['lithium'] @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar depression'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine']
@entity162 :: (MESH:D001714,Disease) :: ['bipolar depression']
